Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 3/20 | 0.49 |
| ▸ | CDK4 | P11802 | 3/20 | 0.49 |
| ▸ | CCND1 | P24385 | 3/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CCND2 | P30279 | 2/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28058542 | 0.92 | CCND3 (0.44) | CCND3CDK4CCND1CCNA2CDK2 | |
| SCHEMBL5264282 | 0.81 | CDK4 (0.52) | CCND3CDK4CCND1CCNA2CDK2 | |
| SCHEMBL17687572 | 0.78 | CCND3 (0.46) | CCND3CDK4CCND1CCNA2CDK2 | |
| SCHEMBL2320862 | 0.77 | EGFR (0.43) | CCND3CDK4CCND1CCNA2CDK2 | |
| SCHEMBL19882756 | 0.77 | CCND3 (0.41) | CCND3CDK4CCND1CCNA2CDK2 | |
| SCHEMBL4075363 | 0.77 | CDK4 (0.50) | CCND3CDK4CCND1CCNA2CDK2 | |
| SCHEMBL16416249 | 0.73 | MAPK8 (0.48) | CCNA2CDK2CCNKALDH1A1MAPK10 | |
| SCHEMBL1133352 | 0.72 | KMT2A (0.48) | CCND3CDK4CCND1CCNA2CDK2 | |
| SCHEMBL4722863 | 0.71 | CDK4 (0.62) | CCND3CDK4CCND1CCNA2CDK2 | |
| SCHEMBL6402766 | 0.71 | KMT2A (0.47) | CCND3CDK4CCND1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | claimed |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-08-01 | — | — | US | claimed |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-03-08 | — | — | US | claimed |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-08-11 | — | — | US | claimed |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2021-06-24 | — | — | US | disclosed |
| US-10934528-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3718560-A2 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | The University of North Carolina at Chapel Hill (US) | 2020-10-07 | — | — | EP | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050171182-A1 | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases | THERAVANCE, INC. | 2005-08-04 | — | — | US | disclosed |
| WO-2005058341-A2 | COMPOSITIONS FOR USE IN THE TREATMENT OF MUTANT RECEPTOR TYROSINE KINASE DRIVEN CELLULAR PROLIFERATIVE DISEASES | THERAVANCE, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| EP-1470124-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003062236-A8 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | CCND3 686/4885CDK4 36/4885CCND1 522/4885 |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | CCND3 686/4885CDK4 36/4885CCND1 522/4885 |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | CCND3 44/4885CDK4 1/4885CCND1 27/4885 |
| US-20050171182-A1 | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases | CDK4, BRAF, CDK2 | CCND3 255/4885CDK4 1/4885CCND1 250/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | CCND3 560/4885CDK4 27/4885CCND1 408/4885 |
| US-10934528-B2 | Reprogramming of cells to a new fate | ALPG, POU5F1, POU2F1 | CCND3 4522/4885CDK4 4056/4885CCND1 4462/4885 |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | CCND3 686/4885CDK4 36/4885CCND1 522/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | CCND3 686/4885CDK4 36/4885CCND1 522/4885 |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | ALPG, POU5F1, POU2F1 | CCND3 4522/4885CDK4 4056/4885CCND1 4462/4885 |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | CCND3 686/4885CDK4 36/4885CCND1 522/4885 |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | CCND3 686/4885CDK4 36/4885CCND1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.